59303-17-2

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(5-methyl-2-thiazolyl)(9CI) is utilized as a synthetic intermediate for the development of pharmaceuticals. Its unique structure and reactivity make it a valuable building block for the synthesis of complex molecules with diverse biological properties, contributing to the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Ethanone, 1-(5-methyl-2-thiazolyl)(9CI) serves as a synthetic intermediate for the production of agrochemicals. Its properties allow for the synthesis of compounds with potential applications in agriculture, such as pesticides, herbicides, and other crop protection agents, enhancing crop yield and quality.
Used in Organic Synthesis:
Ethanone, 1-(5-methyl-2-thiazolyl)(9CI) is employed as a synthetic intermediate in organic synthesis, enabling the creation of a wide range of organic compounds with various applications across different industries. Its unique thiazole ring structure and reactivity make it a valuable component in the synthesis of complex molecules with diverse chemical properties.

Upstream product

• 3581-89-3 5-methylthiazole 
• 68-12-2 N,N-dimethyl-formamide 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 220270-61-1 2-bromo-1-(5-methyl-thiazol-2-yl)-ethanone 
• 921145-14-4 N-methyl-1-(5-methylthiazol-2-yl)methanamine 

Relevant academic research and scientific papers

CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.

DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)

A series of SYK inhibitors based on the phenylamino pyrimidine thiazole lead 4 were prepared and evaluated for biological activity. Lead optimization provided compounds with nanomolar Ki's against SYK and potent inhibition in mast cell degranulation assays.

QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR

An objective of the present invention is to provide compounds which have inhibitory activity against autophosphorylation of macrophage colony-stimulating factor receptors. The compounds of the present invention are represented by formula (I) and salt and solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, optionally substituted alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkyl, alkoxy, trifluoromethyl or the like; R9 and R10 represent H, alkyl or the like; and any one of R11 and R12 represents H with the other representing alkyl and R13 represents an optionally substituted carbocyclic or heterocyclic ring or the like, or R11 represents H and R12 and R13 combine together to form a bicyclic carbocyclic ring.